



**CMD 26-H110.8**

Date: 2026-06-22

**Written Submission from the  
London Health Sciences Centre**

**Mémoire du  
Centre des Sciences de la Santé  
de London**

In the matter of

À l'égard du

**Bruce Power**

---

**Bruce Power**

---

Application to change the lutetium-177  
production process at Bruce A and B  
Nuclear Generating Stations

Demande visant à modifier le processus de  
production de lutécium 177 aux centrales  
nucléaires de Bruce A et B

**Hearing in Writing**

**Audience par écrit**

July 2026

Juillet 2026



June 18, 2026

Canadian Nuclear Safety Commission  
280 Slater Street  
P.O. Box 1046, Station B  
Ottawa, Ontario K1P 5S9

Subject: Public Submission in Support of Bruce Power's Hot Cell Application at the Central Maintenance Facility

To the Canadian Nuclear Safety Commission,

**Re: Letter of Support for Bruce Power's Expansion of Hot Cell Capacity**

I am pleased to provide this letter in strong support of Bruce Power's efforts to expand hot cell capacity in Ontario. As demand grows for reliable supplies of medical isotopes used in cancer diagnosis, treatment, sterilization, and emerging theranostic applications, strengthening domestic isotope-processing infrastructure is essential to patient care, health-system resilience, and Canada's continued leadership in nuclear medicine.

Bruce Power has an established and internationally significant track record in medical isotope production. Its long-standing production of cobalt-60 has supported global sterilization of single-use medical devices, implants, and equipment, while its pioneering production of lutetium-177 through the Isotope Production System has opened new opportunities for precision oncology and targeted radionuclide therapy. These isotopes are directly relevant to the care of patients with cancers such as prostate cancer and neuroendocrine tumours, and they are increasingly important as clinical demand for theranostics continues to rise.

Expanded hot cell capacity at the Bruce Power site would provide a critical next step in building a more complete, efficient, and secure isotope supply chain in Ontario. Hot cells enable the safe handling of irradiated materials and support specialized activities such as target carrier removal prior to downstream radiochemical processing. Locating more of this work on site would streamline logistics, reduce reliance on multiple offsite handling locations, improve operational safety, decrease transport-related emissions, and help ensure that time-sensitive isotopes can move more efficiently from production to processing and ultimately to patients.

This expansion also aligns with broader provincial and national priorities: repatriating and expanding medical isotope processing capacity, supporting advanced manufacturing and nuclear-sector jobs, strengthening Canadian supply chains, and ensuring that Ontario remains a global hub for cancer-fighting isotope innovation. In addition, Bruce Power's partnership with Saugeen Ojibway Nation through Gamzook'aamin aakoziwin demonstrates how medical isotope development can advance both health innovation and meaningful economic participation for Indigenous communities.

From a clinical and academic medical imaging perspective, the need for dependable access to therapeutic and diagnostic isotopes is clear. Hospitals, cancer programs, radiopharmacies, researchers, and patients all benefit when isotope production and processing are reliable, scalable, and located within a robust domestic ecosystem. Expanded hot cell capacity would help position Ontario to meet growing demand, support research into new radiopharmaceuticals, and reduce vulnerabilities associated with complex international supply chains.

For these reasons, I strongly support Bruce Power's proposal to expand hot cell capacity. This investment will strengthen Ontario's medical isotope infrastructure, enhance patient access to life-saving therapies, support



innovation in precision medicine, and reinforce Canada's role as a trusted global leader in the production and handling of medical isotopes.

Sincerely,

---

*Narinder S Paul BM, MRCP (UK), FRCR (UK), FRCPC*

*Professor of Cardiothoracic Imaging  
Chair, Department of Medical Imaging, Western University  
Department Head, Medical Imaging, London Health Sciences and St Josephs'  
Scientist, Robarts and Lawson Research Institutes  
Provincial Lead: Oncology Medical Imaging and Intervention in Ontario*

c/o C2-226, London Health Sciences Centre – University Hospital,  
339 Windermere Rd., London, ON, N6A 5A5